John P H Wilding

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8540760/publications.pdf

Version: 2024-02-01

341 papers	36,187 citations	8732 75 h-index	3476 182 g-index
361 all docs	361 docs citations	361 times ranked	27234 citing authors

#	Article	IF	Citations
1	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLAREâ€“TIMI 58 trial. European Heart Journal, 2022, 43, 2958-2967.	1.0	28
2	Longâ€term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104â€week extension to a 52â€week randomized, phase 3 study and liver fat <scp>MRI</scp> substudy. Diabetes, Obesity and Metabolism, 2022, 24, 61-71.	2.2	4
3	Exercise in Obesityâ€”the Role of Technology in Health Services: Can This Approach Work?. Current Obesity Reports, 2022, 11, 93-106.	3.5	11
4	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	4.3	20
5	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	4.3	10
6	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	1.2	5
7	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension. Diabetes, Obesity and Metabolism, 2022, 24, 1553-1564.	2.2	151
8	The effects of empagliflozin, dietary energy restriction, or both on appetiteâ€regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The <scp>SEESAW</scp> randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1509-1521.	2.2	5
9	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13
10	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 2022, 45, 2396-2405.	4.3	19
11	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€“glucose coâ€transporter 2 inhibitor therapy in <scp>DECLAREâ€TIMI</scp> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	2.9	35
12	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Annals of Medicine, 2021, 53, 2072-2089.	1.5	27
13	The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. Diabetologia, 2021, 64, 288-303.	2.9	26
14	Cardiovascular outcome trials in obesity: A review. Obesity Reviews, 2021, 22, e13112.	3.1	41
15	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€lowering agents: Post hoc analyses from <scp>DECLAREâ€TIMI</scp> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	2.2	28
16	The costâ€effectiveness of dapagliflozin in treating highâ€risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	2.2	19
17	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	2.9	15
18	Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?. BMJ Open, 2021, 11, e044519.	0.8	0

#	Article	IF	Citations
19	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	4.3	25
20	Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 384, 989-1002.	13.9	1,374
21	Short-Term Physical Inactivity Induces Endothelial Dysfunction. Frontiers in Physiology, 2021, 12, 659834.	1.3	6
22	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). Journal of the Endocrine Society, 2021, 5, A10-A10.	0.1	0
23	Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open, 2021, 11, e043906.	0.8	23
24	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
25	Dapagliflozin for the treatment of type 2 diabetes mellitus â€“ an update. Expert Opinion on Pharmacotherapy, 2021, 22, 2303-2310.	0.9	8
26	A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ Open, 2021, 11, e045663.	0.8	8
27	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	4.3	49
28	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	3.0	26
29	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	6.3	222
30	Metabolically healthy obesity: time for a change of heart?. Nature Reviews Endocrinology, 2021, 17, 519-520.	4.3	4
31	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	4.3	13
32	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. International Journal of Obesity, 2021, 45, 923-933.	1.6	28
33	Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Global Health, 2021, 6, e006351.	2.0	107
34	Etiopathogenesis of Obesity. , 2021, , 1-12.		0
35	PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviouR after barlatric Surgery. BMJ Open, 2021, 11, e051638.	0.8	1
36	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	0.9	12

#	Article	IF	Citations
37	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€“TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	4.3	72
38	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 27-35.	5.5	215
39	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides, 2020, 125, 170208.	1.2	39
40	Weight loss is the major player in bariatric surgery benefits. Nature Medicine, 2020, 26, 1678-1679.	15.2	3
41	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	1.6	44
42	Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apneaâ€“hypnoea index (AHI). BMJ Open, 2020, 10, e038856.	0.8	9
43	Assessing the costâ€effectiveness of sodiumâ€“glucose cotransporterâ€2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 2364-2374.	2.2	33
44	Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity. Global Health Action, 2020, 13, 1804700.	0.7	11
45	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Research and Care, 2020, 8, e001706.	1.2	31
46	The 1Î±,25(OH)₂D₃ Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-ÎºB and MAPK Signaling . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1715-1724.	1.1	1
47	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. Future Cardiology, 2020, 16, 77-88.	0.5	6
48	Mechanisms, screening modalities and treatment options for individuals with nonâ€alcoholic fatty liver disease and type 2 diabetes. Diabetic Medicine, 2020, 37, 1793-1806.	1.2	9
49	Cover Image, Volume 22, Issue 7. Diabetes, Obesity and Metabolism, 2020, 22, .	2.2	0
50	Dapagliflozin plus saxagliptin addâ€on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1094-1101.	2.2	28
51	Cardiovascular and renal benefits of dapagliflozin in patients with short and longâ€standing type 2 diabetes: Analysis from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1122-1131.	2.2	16
52	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
53	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	2.2	26
54	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 2020, 28, 1050-1061.	1.5	148

#	Article	IF	Citations
55	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 2757-2774.	1.2	20
56	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open, 2020, 10, e034137.	0.8	5
57	Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. European Journal of Endocrinology, 2020, 183, 211-220.	1.9	10
58	Endocrine testing in obesity. European Journal of Endocrinology, 2020, 182, C13-C15.	1.9	10
59	1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. Diabetes, 2020, 69, 1101-P.	0.3	3
60	303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial. Diabetes, 2020, 69, .	0.3	1
61	Should obesity be recognised as a disease?. BMJ: British Medical Journal, 2019, 366, l4258.	2.4	21
62	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2019, 155, 107791.	1.1	6
63	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1câ€"Translating Evidence into Practice. Diabetes Therapy, 2019, 10, 1595-1622.	1.2	36
64	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy, 2019, 10, 2201-2217.	1.2	11
65	410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus. European Heart Journal, 2019, 40, .	1.0	0
66	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	1.6	94
67	Semaglutide in weight management â€“ Author's reply. Lancet, The, 2019, 394, 1226-1227.	6.3	2
68	Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. Diabetes Therapy, 2019, 10, 1995-2021.	1.2	63
69	1Î±,25(OH)2D3 attenuates IL-6 and IL-1Î²-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-ÎºB signaling pathways. Diabetology and Metabolic Syndrome, 2019, 11, 9.	1.2	2
70	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€"TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	5.5	482
71	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 9-18.	2.2	69
72	Incorporating patientsâ€™ perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000615.	1.2	22

#	Article	IF	Citations
73	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
74	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
75	DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. Journal of the American College of Cardiology, 2019, 73, 1.	1.2	2
76	Weight loss variability with SGLT2 inhibitors and GLPâ€1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obesity Reviews, 2019, 20, 816-828.	3.1	139
77	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
78	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000700.	1.2	42
79	Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. Medicine and Science in Sports and Exercise, 2019, 51, 1169-1177.	0.2	40
80	SGLT2 inhibitors and urinary tract infections. Nature Reviews Endocrinology, 2019, 15, 687-688.	4.3	21
81	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	13.9	4,159
82	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	6.3	1,958
83	1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. Diabetes, 2019, 68, .	0.3	1
84	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. Diabetes, 2019, 68, 244-OR.	0.3	11
85	Response by Kosiborod et al to Letters Regarding Article, â€œLower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	6
86	Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. Diabetologia, 2018, 61, 1282-1294.	2.9	91
87	Beyond lifestyle interventions: exploring the potential of antiâ€obesity medications in the UK. Clinical Obesity, 2018, 8, 211-225.	1.1	10
88	Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. Appetite, 2018, 125, 270-277.	1.8	7
89	Newer GLP-1 receptor agonists and obesity-diabetes. Peptides, 2018, 100, 61-67.	1.2	54
90	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	1.2	117

#	Article	IF	Citations
91	<scp>DECLAREâ€TIMI</scp> 58: Participantsâ€™ baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	2.2	96
92	Obesity and Obstructive Sleep Apnea Syndrome. Endocrinology, 2018, , 1-30.	0.1	0
93	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	1.2	370
94	Rates of myocardial infarction and stroke in patients initiating treatment with <scp>SGLT</scp>2â€inhibitors versus other glucoseâ€lowering agents in realâ€world clinical practice: <scp>R</scp>esults from the <scp>CVDâ€REAL</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1983-1987.	2.2	65
95	Medication use for the treatment of diabetes in obese individuals. Diabetologia, 2018, 61, 265-272.	2.9	35
96	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 146, 240-250.	1.1	17
97	Time for a new obesity narrative. Lancet, The, 2018, 392, 1384-1386.	6.3	50
98	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. Obesity Reviews, 2018, 19, 1569-1584.	3.1	34
99	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. Trials, 2018, 19, 427.	0.7	12
100	SGLT-2 Inhibitors and Cardiovascular Risk. Journal of the American College of Cardiology, 2018, 71, 2497-2506.	1.2	113
101	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.	2.2	87
102	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6â€“10. Diabetes Care, 2018, 41, e106-e108.	4.3	8
103	Vitamin D receptor ligands attenuate the inflammatory profile of IL-1Î²-stimulated human white preadipocytes via modulating the NF-Î°B and unfolded protein response pathways. Biochemical and Biophysical Research Communications, 2018, 503, 1049-1056.	1.0	19
104	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Therapy, 2018, 9, 1757-1773.	1.2	53
105	Changes in HbA1c and weight, and treatment persistence, over the 18Âmonths following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine, 2018, 16, 116.	2.3	36
106	Patientsâ€™ Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. Diabetes Therapy, 2018, 9, 1791-1810.	1.2	16
107	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, The, 2018, 392, 637-649.	6.3	446
108	Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetesâ€”The Energize Study. Diabetes, 2018, 67, .	0.3	4

#	Article	IF	Citations
109	HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in U.K. Primary Care Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	0
110	A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin. Diabetes, 2018, 67, 1131-P.	0.3	0
111	Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	0
112	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1191-P.	0.3	0
113	Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)â€"study protocol. BMJ Open, 2017, 7, e013539.	0.8	15
114	What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. International Journal of Obesity, 2017, 41, 853-865.	1.6	93
115	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	6.3	502
116	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 141-147.	1.8	9
117	Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews, 2017, 18, 715-723.	3.1	846
118	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E224-E233.	1.8	41
119	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice, 2017, 71, e12948.	0.8	20
120	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017, 136, 249-259.	1.6	672
121	Screening methods for obstructive sleep apnoea in severely obese pregnant women. Clinical Obesity, 2017, 7, 239-244.	1.1	4
122	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	5.5	248
123	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes, Obesity and Metabolism, 2017, 19, 1529-1536.	2.2	52
124	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.3	454
125	Evaluation of Aintree <scp>LOSS</scp>, a communityâ€based, multidisciplinary weight management service: outcomes and predictors of engagement. Clinical Obesity, 2017, 7, 368-376.	1.1	12
126	Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. Experimental Physiology, 2017, 102, 1424-1434.	0.9	16

#	Article	IF	Citations
127	Combination therapy for obesity. Journal of Psychopharmacology, 2017, 31, 1503-1508.	2.0	28
128	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Primary Care Diabetes, 2017, 11, 437-444.	0.9	22
129	SAT0209â€...Observational study on the effects of il-6 inhibitor therapy on myostatin in patients with rheumatoid arthritis. , 2017, , .		1
130	SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. Trials, 2017, 18, 597.	0.7	14
131	Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. Journal of Obesity, 2016, 2016, 1-12.	1.1	14
132	Energy balance and metabolic changes with sodiumâ€glucose coâ€transporter 2 inhibition. Diabetes, Obesity and Metabolism, 2016, 18, 125-134.	2.2	76
133	Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Therapy, 2016, 7, 695-711.	1.2	20
134	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	1.7	2
135	GLP-1 as a target for therapeutic intervention. Current Opinion in Pharmacology, 2016, 31, 44-49.	1.7	32
136	Exposureâ€“response analyses of liraglutide 3.0â€‰mg for weight management. Diabetes, Obesity and Metabolism, 2016, 18, 491-499.	2.2	52
137	Role of incretinâ€based therapies and sodiumâ€glucose coâ€transporterâ€2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. Diabetic Medicine, 2016, 33, 864-876.	1.2	7
138	Weighing up dietary patterns â€“ Authors' reply. Lancet, The, 2016, 388, 759-760.	6.3	3
139	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	1.3	21
140	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. Diabetes Care, 2016, 39, S154-S164.	4.3	36
141	Early Weight Loss with Liraglutide 3.0 mg Predicts 1â€Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity, 2016, 24, 2278-2288.	1.5	88
142	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. Lancet Diabetes and Endocrinology,the, 2016, 4, 379-381.	5.5	6
143	Fit for <scp>B</scp>irth â€“ the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study. Clinical Obesity, 2016, 6, 79-88.	1.1	11
144	Management of obesity. Lancet, The, 2016, 387, 1947-1956.	6.3	715

#	Article	IF	Citations
145	Etiopathogenesis of Obesity. , 2016, , 13-20.		1
146	Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes. Endocrinology Metabolism & Genetics, 2016, 1, .	0.0	4
147	An observation of gestational weight gain in obese pregnancies. Proceedings of the Nutrition Society, 2015, 74, .	0.4	0
148	Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. International Journal of Clinical Practice, 2015, 69, 186-198.	0.8	14
149	Obesity as a disability: a weighty precedent?. Clinical Obesity, 2015, 5, 163-164.	1.1	1
150	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
151	Serum urate and obstructive sleep apnoea in severe obesity. Chronic Respiratory Disease, 2015, 12, 238-246.	1.0	10
152	Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. Sleep Science, 2015, 8, 58-67.	0.4	6
153	Pathophysiology and aetiology of obesity. Medicine, 2015, 43, 73-76.	0.2	15
154	Impact of bariatric surgery on physical functioning in obese adults. Obesity Reviews, 2015, 16, 248-258.	3.1	42
155	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 2015, 373, 11-22.	13.9	1,492
156	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 438-444.	1.2	43
157	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58, 1183-1187.	2.9	118
158	Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. Sleep and Breathing, 2015, 19, 1155-1165.	0.9	14
159	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	6.3	659
160	Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. International Journal of Obesity, 2015, 39, 1376-1382.	1.6	4
161	SGLT2 inhibition and ketoacidosis â€“ should we be concerned?. British Journal of Diabetes and Vascular Disease, 2015, 15, 155.	0.6	10
162	The clinical management of diabetes mellitus. , 2014, , 305-332.		4

#	Article	IF	Citations
163	A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. Expert Opinion on Drug Safety, 2014, 13, 1535-1544.	1.0	8
164	Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease. Diabetes Care, 2014, 37, 483-487.	4.3	58
165	Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. Clinical Science, 2014, 127, 655-663.	1.8	8
166	Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. Chronic Respiratory Disease, 2014, 11, 257-275.	1.0	51
167	Characteristics and perspectives of nightâ€eating behaviour in a severely obese population. Clinical Obesity, 2014, 4, 30-38.	1.1	16
168	Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ, The, 2014, 349, g6608-g6608.	3.0	158
169	Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 2014, 44, 1104-1115.	1.7	14
170	Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. Journal of Sleep Research, 2014, 23, 700-708.	1.7	27
171	Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism, 2014, 16, 159-169.	2.2	391
172	The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism: Clinical and Experimental, 2014, 63, 1228-1237.	1.5	139
173	Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes, Obesity and Metabolism, 2014, 16, 124-136.	2.2	239
174	The importance of weight management in type 2 diabetes mellitus. International Journal of Clinical Practice, 2014, 68, 682-691.	0.8	209
175	Liraglutide in the treatment of obesity. Expert Opinion on Biological Therapy, 2014, 14, 1215-1224.	1.4	17
176	Glucose metabolism and the pathophysiology of diabetes mellitus. , 2014, , 273-304.		3
177	Obstructive sleep apnoea in diabetes - assessment and awareness. British Journal of Diabetes and Vascular Disease, 2014, 14, 105.	0.6	6
178	Screening for obstructive sleep apnoea in obesity and diabetes â€“ potential for future approaches. European Journal of Clinical Investigation, 2013, 43, 640-655.	1.7	21
179	Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opinion on Emerging Drugs, 2013, 18, 375-391.	1.0	8
180	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261

#	Article	IF	Citations
181	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2013, 27, 268-273.	1.2	76
182	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International Journal of Clinical Practice, 2013, 67, 1267-1282.	0.8	281
183	Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. Sleep Medicine, 2013, 14, 1151-1156.	0.8	17
184	Acute peripheral administration of synthetic human GLP-1 (7â€“36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. Regulatory Peptides, 2013, 183, 54-61.	1.9	29
185	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a doseâ€finding study. Diabetes, Obesity and Metabolism, 2013, 15, 403-409.	2.2	103
186	Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. Canadian Journal of Diabetes, 2013, 37, S29.	0.4	0
187	Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. Endocrine, 2013, 43, 696-704.	1.1	10
188	Orlistat: should we worry about liver inflammation?. BMJ, The, 2013, 346, f2777-f2777.	3.0	9
189	Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. European Journal of Endocrinology, 2013, 168, 501-507.	1.9	22
190	How to approach endocrine assessment in severe obesity?. Clinical Endocrinology, 2013, 79, 163-167.	1.2	14
191	Doseâ€ranging study with the glucokinase activator <scp>AZD1656</scp> in patients with type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism, 2013, 15, 750-759.	2.2	74
192	232 DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENSOIS WITH A NORMAL EJECTION FRACTION. Heart, 2013, 99, A125.1-A125.	1.2	0
193	1,25-dihydroxyvitamin D3 Protects against Macrophage-Induced Activation of NFÎºB and MAPK Signalling and Chemokine Release in Human Adipocytes. PLoS ONE, 2013, 8, e61707.	1.1	88
194	The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. Thorax, 2012, 67, 920-924.	2.7	32
195	Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1020-1031.	1.8	689
196	Night eating syndrome: implications for severe obesity. Nutrition and Diabetes, 2012, 2, e44-e44.	1.5	60
197	Facing the Challenges for Europe Â– Research into Action: Liverpool European Congress of Obesity, May 12Â–15, 2013. Obesity Facts, 2012, 5, 629-634.	1.6	2
198	Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma. Chest, 2012, 141, 616-624.	0.4	53

#	Article	IF	Citations
199	High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. Proceedings of the Nutrition Society, 2012, 71, .	0.4	0
200	Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin. Annals of Internal Medicine, 2012, 156, 405.	2.0	402
201	A glucagonâ€like peptideâ€1 (<scp>GLP</scp>â€1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clinical Endocrinology, 2012, 77, 635-637.	1.2	25
202	Vitamin D signalling in adipose tissue. British Journal of Nutrition, 2012, 108, 1915-1923.	1.2	261
203	Anti-obesity drugs: past, present and future. DMM Disease Models and Mechanisms, 2012, 5, 621-626.	1.2	360
204	Are the causes of obesity primarily environmental? Yes. BMJ, The, 2012, 345, e5843-e5843.	3.0	20
205	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes, Obesity and Metabolism, 2012, 14, 973-982.	2.2	59
206	Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism, 2012, 14, 990-999.	2.2	176
207	Reply to Camargo etâ€ƒal. Diabetic Medicine, 2012, 29, 1086-1087.	1.2	0
208	Effects of chronic treatment with metformin on dipeptidyl peptidaseâ€4 activity, glucagonâ€like peptideâ€ƒ1 and ghrelin in obese patients with Typeâ€ƒ2 diabetes mellitus. Diabetic Medicine, 2012, 29, e205-10.	1.2	38
209	Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ: British Medical Journal, 2011, 342, d410.	2.4	18
210	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Typeâ€ƒ2 diabetic chronic kidney disease. Diabetic Medicine, 2011, 28, 1279-1279.	1.2	8
211	Human RBP4 adipose tissue expression is gender specific and influenced by leptin. Clinical Endocrinology, 2011, 74, 197-205.	1.2	31
212	Pathophysiology and aetiology of obesity. Medicine, 2011, 39, 6-10.	0.2	8
213	The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. Diabetologia, 2011, 54, 1304-1307.	2.9	43
214	Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. European Journal of Endocrinology, 2011, 165, 45-55.	1.9	11
215	The endocrinologist and respiratory failure. , 2010, , 391-398.		0
216	Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. Age, 2010, 32, 209-222.	3.0	37

#	Article	IF	Citations
217	From history to reality: sodium glucose coâ€transporter 2 inhibitors â€“ a novel therapy for type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 311-316.	0.2	11
218	The adipokine zincâ€Î±2â€glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clinical Endocrinology, 2010, 72, 334-341.	1.2	102
219	Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. Clinical Endocrinology, 2010, 73, 678-685.	1.2	24
220	In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIFâ€1. Diabetes, Obesity and Metabolism, 2010, 12, 360-363.	2.2	7
221	Nurseâ€led clinics for strict hypertension control are effective long term: a 7â€fyear followâ€up study. Diabetic Medicine, 2010, 27, 933-937.	1.2	7
222	Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 34-42.	1.8	225
223	The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. Journal of Psychopharmacology, 2010, 24, 99-109.	2.0	38
224	SPARC: a key player in the pathologies associated with obesity and diabetes. Nature Reviews Endocrinology, 2010, 6, 225-235.	4.3	141
225	Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose. Diabetes, 2009, 58, 1780-1788.	0.3	108
226	A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers. Diabetes Care, 2009, 32, 1656-1662.	4.3	346
227	Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes. Endocrinology, 2009, 150, 1688-1696.	1.4	161
228	Modern management of obesity. Clinical Medicine, 2009, 9, 617-621.	0.8	4
229	Effects of peripheral administration of synthetic human glucoseâ€dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clinical Endocrinology, 2009, 71, 195-201.	1.2	52
230	Ghrelin restores â€˜lean-typeâ€™ hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. International Journal of Obesity, 2009, 33, 317-325.	1.6	35
231	Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. Diabetes, Obesity and Metabolism, 2009, 11, 733-741.	2.2	29
232	Identification of macrophage inhibitory cytokine-1 (MIC-1) in adipose tissue and its secretion as an adipokine by human adipocytes. Proceedings of the Nutrition Society, 2009, 68, .	0.4	0
233	The aipokine zinc-Î±2-glycoprotein is down regulated with fat mass expansion in obesity. Proceedings of the Nutrition Society, 2009, 68, .	0.4	0
234	Adipokines: emerging therapeutic targets. Current Opinion in Investigational Drugs, 2009, 10, 1061-8.	2.3	6

#	Article	IF	Citations
235	Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 54-58.	0.2	1
236	Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. International Journal of Obesity, 2008, 32, 129-135.	1.6	60
237	Energy restriction enhances therapeutic efficacy of the PPARÎ³ agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes, Obesity and Metabolism, 2008, 10, 251-263.	2.2	9
238	Growth hormone and changes in energy balance in growth hormone deficient adults. European Journal of Clinical Investigation, 2008, 38, 622-627.	1.7	10
239	Anti-obesity Drugs: From Animal Models to Clinical Efficacy. , 2008, , 271-315.		7
240	Sleep-disordered breathing and type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 81, 2-12.	1.1	276
241	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. British Journal of Diabetes and Vascular Disease, 2008, 8, 170-176.	0.6	2
242	Intestinal lipase inhibitors. , 2008, , 47-57.		0
243	The endocannabinoid system as a target for obesity treatment. , 2008, , 69-80.		0
244	Clinical Investigations of Antiobesity Drugs. , 2007, , 337-III.		4
245	Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2007, 4, 194-203.	0.9	38
246	Cardiovascular and metabolic effects of CPAP in obese males with OSA. European Respiratory Journal, 2007, 29, 720-727.	3.1	278
247	Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. Postgraduate Medical Journal, 2007, 83, 277-280.	0.9	27
248	Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. Journal of Psychopharmacology, 2007, 21, 405-413.	2.0	95
249	Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Bone, 2007, 41, 406-413.	1.4	30
250	Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. Nutrition and Metabolism, 2007, 4, 15.	1.3	13
251	A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1696-1704.	1.2	193
252	Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 299-303.	1.7	32

#	Article	IF	Citations
253	An elderly type 1 diabetic patient with life event-related brittle diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 130-131.	0.2	0
254	Treatment strategies for obesity. Obesity Reviews, 2007, 8, 137-144.	3.1	27
255	Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. Diabetes, Obesity and Metabolism, 2007, 9, 114-120.	2.2	18
256	The importance of free fatty acids in the development of TypeÂ2 diabetes. Diabetic Medicine, 2007, 24, 934-945.	1.2	153
257	Obesity and risk of myocardial infarction: the INTERHEART study. Lancet, The, 2006, 367, 1053.	6.3	5
258	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabetic Medicine, 2006, 23, 780-787.	1.2	35
259	Applied physiology: The control of weight. Current Paediatrics, 2006, 16, 439-446.	0.2	0
260	Gut peptides and the regulation of appetite. Obesity Reviews, 2006, 7, 163-182.	3.1	190
261	Thiazolidinediones, insulin resistance and obesity: finding a balance. International Journal of Clinical Practice, 2006, 60, 1272-1280.	0.8	62
262	Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. Diabetologia, 2006, 49, 2219-2221.	2.9	17
263	Pathophysiology and aetiology of obesity. Medicine, 2006, 34, 501-505.	0.2	8
264	Diabetes and sleep apnoea: a hidden epidemic?. Thorax, 2006, 61, 928-929.	2.7	1
265	Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgraduate Medical Journal, 2006, 82, 280-284.	0.9	240
266	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2005, 7, 755-761.	2.2	119
267	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. Diabetic Medicine, 2005, 22, 666-667.	1.2	2
268	Improved glycaemic control-an unintended benefit of a nurse-led cardiovascular risk reduction clinic. Diabetic Medicine, 2005, 22, 1272-1274.	1.2	23
269	The dual PPARÎ± /Î³ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. British Journal of Pharmacology, 2005, 144, 308-316.	2.7	71
270	Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia, 2005, 48, 2641-2649.	2.9	33

#	Article	IF	Citations
271	A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology, 2005, 181, 80-89.	1.5	115
272	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart, 2005, 91, 32-37.	1.2	58
273	Is There a Role for Ghrelin and Peptide-YY in the Pathogenesis of Obesity in Adults with Acquired Structural Hypothalamic Damage?. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5025-5030.	1.8	25
274	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Medicine, 2004, 21, 415-422.	1.2	71
275	The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. Clinical Endocrinology, 2004, 60, 137-141.	1.2	33
276	Body weight and prolactinoma: a retrospective study. International Journal of Obesity, 2004, 28, 183-183.	1.6	8
277	A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity, 2004, 28, 1399-1410.	1.6	194
278	Response: Postprandial Adiponectin Revisited. Obesity, 2004, 12, 1032-1034.	4.0	5
279	Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. Brain Research, 2004, 1016, 222-228.	1.1	21
280	Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. Diabetes/Metabolism Research and Reviews, 2004, 20, 405-410.	1.7	26
281	Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. European Heart Journal, 2004, 25, 735-741.	1.0	683
282	Obesity treatment: the key to managing the type 2 diabetes timebomb?. British Journal of Diabetes and Vascular Disease, 2004, 4, 217-219.	0.6	0
283	Clinical Evaluation of Anti-Obesity Drugs. Current Drug Targets, 2004, 5, 325-332.	1.0	12
284	Pathophysiology and Aetiology of Obesity. Medicine, 2003, 31, 1-4.	0.2	1
285	Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 513-514.	0.9	0
286	Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and Î²-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. International Journal of Experimental Pathology, 2003, 84, 83-89.	0.6	14
287	Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clinical Endocrinology, 2003, 59, 75-81.	1.2	36
288	Plasma Adiponectin Increases Postprandially in Obese, but not in Lean, Subjects. Obesity, 2003, 11, 839-844.	4.0	61

#	Article	IF	Citations
289	Intensified treatment of type 2 diabetesâ€"positive effects on blood pressure, but not glycaemic control. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 833-836.	0.2	27
290	Obesity and Type-2 Diabetes in the Elderly. Gerontology, 2003, 49, 137-145.	1.4	10
291	P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. European Heart Journal, 2003, 24, 159.	1.0	0
292	Food Fails to Suppress Ghrelin Levels in Obese Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2984-2984.	1.8	411
293	Ghrelin: sweet regulation?. Clinical Science, 2002, 103, 329-330.	1.8	1
294	Obesity: under-diagnosed and under-treated in hospital outpatient departments. International Journal of Obesity, 2002, 26, 581-584.	1.6	16
295	Neuropeptides and appetite control. Diabetic Medicine, 2002, 19, 619-627.	1.2	155
296	Hypothalamic obesity in humans: what do we know and what can be done?. Obesity Reviews, 2002, 3, 27-34.	3.1	66
297	Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. International Journal of Clinical Practice, 2002, 56, 494-9.	0.8	65
298	Leptin and the control of obesity. Current Opinion in Pharmacology, 2001, 1, 656-661.	1.7	31
299	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clinical Science, 2001, 100, 635-641.	1.8	47
300	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. Clinical Science, 2001, 101, 499-506.	1.8	47
301	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clinical Science, 2001, 100, 635.	1.8	18
302	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. Clinical Science, 2001, 101, 499.	1.8	20
303	An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clinical Endocrinology, 2001, 54, 463-468.	1.2	121
304	The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. Clinical Endocrinology, 2001, 54, 819-826.	1.2	18
305	Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes, Obesity and Metabolism, 2001, 3, 171-180.	2.2	22
306	Sleep disordered breathing - a new component of syndrome x?. Obesity Reviews, 2001, 2, 267-274.	3.1	43

#	Article	IF	Citations
307	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. British Journal of Pharmacology, 2001, 132, 1898-1904.	2.7	35
308	Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. European Journal of Pharmacology, 2001, 416, 133-139.	1.7	10
309	Evolution of Early Changes in Heart Rate Variability following Acute Myocardial Infarction. Clinical Science, 2000, 99, 15P-16P.	0.0	0
310	Obesity and Type 2 diabetes mellitus. Diabetic Medicine, 2000, 17, 400-402.	1.2	1
311	Management of hypertension. BMJ: British Medical Journal, 2000, 320, 576-576.	2.4	4
312	Abnormal Heart Rate Variability in Adults with Growth Hormone Deficiency1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 628-633.	1.8	21
313	Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine, 2000, 160, 1321.	4.3	312
314	Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. Molecular Brain Research, 2000, 77, 131-137.	2.5	68
315	Abnormal heart rate variability in adults with symptomatic growth hormone (GH) deficiency: improvement after 3 months of GH replacement therapy. Growth Hormone and IGF Research, 2000, 10, S149.	0.5	0
316	The future of obesity treatment. Exs, 2000, 89, 181-191.	1.4	3
317	Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. Postgraduate Medical Journal, 1999, 75, 467-470.	0.9	39
318	Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes, 1999, 48, 2132-2137.	0.3	286
319	Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. British Journal of Pharmacology, 1999, 128, 1570-1576.	2.7	132
320	Obesity and diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 221-237.	2.2	62
321	Sympathovagal Balance in Growth Hormone Deficient Patients. Clinical Science, 1999, 97, 6P-6P.	0.0	0
322	Abdominal Obesity, Impaired Nonesterified Fatty Acid Suppression, and Insulin-Mediated Glucose Disposal Are Early Metabolic Abnormalities in Families With Premature Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1021-1026.	1.1	57
323	Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. Journal of Endocrinology, 1997, 152, 365-369.	1.2	40
324	Endocrine effects of gastrointestinal tumours. Endocrine-Related Cancer, 1997, 4, 179-189.	1.6	1

#	Article	IF	Citations
325	Neurobiology. British Medical Bulletin, 1997, 53, 286-306.	2.7	22
326	Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. Journal of the European Academy of Dermatology and Venereology, 1997, 9, 68-73.	1.3	0
327	Glucagonâ€like peptideâ€1 (GLPâ€1): a trial of treatment in nonâ€insulinâ€dependent diabetes mellitus. European Journal of Clinical Investigation, 1997, 27, 533-536.	1.7	98
328	Science, medicine, and the future: Obesity treatment. BMJ: British Medical Journal, 1997, 315, 997-1000.	2.4	58
329	Metabolic actions of neuropeptide Y and their relevance to obesity. Biochemical Society Transactions, 1996, 24, 576-581.	1.6	5
330	Reduced NPY Induced Feeding in Diabetic but not Steroid-Treated Rats: Lack of Evidence for Changes in Receptor Number or Affinity. Journal of Neuroendocrinology, 1996, 8, 283-290.	1.2	11
331	A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 1996, 379, 69-72.	13.7	1,692
332	E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Research, 1996, 56, 5285-92.	0.4	53
333	Acute Effects of Central Neuropeptide Y Injection on Glucose Metabolism in Fasted Rats. Clinical Science, 1995, 89, 543-548.	1.8	8
334	Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia, 1994, 37, 166-169.	2.9	47
335	Effect of food deprivation and streptozotocin-induced diabetes on hypothalamic neuropeptide Y release as measured by a radioimmunoassay-linked microdialysis procedure. Brain Research, 1994, 656, 135-140.	1.1	36
336	Dietary Advice Based on the Glycaemic Index Improves Dietary Profile and Metabolic Control in Type 2 Diabetic Patients. Diabetic Medicine, 1994, 11, 397-401.	1.2	147
337	Increases in Neuropeptide Y Content and Gene Expression in the Hypothalamus of Rats Treated with Dexamethasone Are Prevented by Insulin. Neuroendocrinology, 1993, 57, 581-587.	1.2	70
338	Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. Journal of Endocrinology, 1992, 132, 299-304.	1.2	82
339	Elevated hypothalamic neuropeptide-Y concentrations in rats fed a palatable diet â€" effect of d-fenfluramine. Regulatory Peptides, 1990, 30, 59.	1.9	0
340	Pharmacological Approaches for Treating Obesity. , 0, , 421-446.		3
341	Drug Therapy for the Obese Diabetic Patient. , 0, , 185-202.		0